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Comparison of urinary 6-13-cortisol and the 
erythromycin breath test as measures of 
hepatic P450IIIA (CYP3A) activity 
The production of "CO2 in the breath from an intravenous dose of ["C-N-methyl]erythromycin (the 
erythromycin breath test [ERMBT]) and the measurement of the ratio of 6-13-cortisol to free cortisol 
(6-0-F/FF) in the urine have each been proposed as means of measuring hepatic P450IIIA catalytic ac- 
tivity in patients. We found that there was a significant correlation between the results of each test (r = 
0.59, p < 0.001) in 47 patients who were without liver disease and who were not taking medications 
believed to influence P45011IA catalytic activity. In the 24 of these patients who were subsequently 
treated with the P450IIIA substrate cyclosporine, the ERNIBT result was highly correlated with the 
mean trough cyclosporine blood level observed; however, there was no correlation between urinary 6-0- 
F/FF and the cyclosporine blood levels. In a separate study of a patient during the anhepatic phase of 
liver transplantation surgery, the ERMBT result decreased by greater than 85%, whereas urinary 6-0- 
F/FF decreased by just 50%. We conclude that the ERNIBT and urinary 6-0-F/FF do not always provide 
similar information about P450IIIA catalytic activity in patients, possibly because of extrahepatic pro- 
duction of 6-13-F. Of the two tests, the ERMBT appears to provide the most relevant information for 
cyclosporine administration. (CLIN PHARMACOL THER 1992;52:265-73.) 
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The P450111A*I enzymes catalyze the major path- 
ways for the metabolism of many commonly used 
medications, including erythromycin,2 cyclosporine,3 
midazolam,4 lidocaine,5 tamoxifen,6 and calcium 
channel blockers.7 P450111A enzymes have also been 
implicated in the bioactivation of potentially toxic en- 
vironmental chemicals such as mycotoxins." There 
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within the CYP3A gene subfamily.' 
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exists at least a tenfold interindividual variation in the 
liver catalytic activity of P450IIIA that may reflect 
both genetic and environmental factors. ' It seems 
likely that this heterogeneity accounts, at least in part, 
for interpatient differences both in the dosing require- 
ments of some drugs and in the susceptibility to some 
environmental diseases. To test these hypotheses it 
would be desirable to have a noninvasive test capable 
of quantitating P450IIIA activity in patients. 
We have proposed that the catalytic activity of 
P450IIIA enzymes in a patient's liver can be inferred 
from the rate at which the patient exhales "CO, after 
receiving a trace intravenous dose of [14C-N-methyll- 
erythromycin." This test is based on the observation 
that P450IIIA exclusively catalyzes the N-demethyla- 
tion of erythromycin in human liver microsomes" and 
the fact that the carbon atom in formaldehyde pro- 
duced by the demethylation should largely appear in 
the breath as carbon dioxide." We believe that the 
erythromycin breath test (ERMBT) selectively mea- 
sures P45011IA activity on the basis of several obser- 
vations. First, the rate of production of breath 14CO2 
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increases significantly in patients after they are treated 
with inducers of P450IIIA and decreases significantly 
in patients after they are treated with triacetyloleando- 
mycin, a known selective inhibitor of P450IIIA. /2 
Second, the ERMBT result obtained in an individual 
patient correlates with the trough blood levels of cy- 
closporine that are observed when the patient receives 
the drug." Finally, we have recently performed a 
study where the ERMBT was administered to nine pa- 
tients with liver disease who were awaiting liver trans- 
plantation.15 We found that there was a significant 
correlation between the preoperative ERMBT result 
and the level of P450IIIA measured directly in the pa- 
tient's liver tissue obtained at the time of transplant 
surgery. In contrast, we found no correlation between 
the breath test result and the liver content of four other 
major P450 enzymes. 
P45011IA enzymes have also been shown to cata- 
lyze the 6-3-hydroxylation of steroid hormones.16 It 
has therefore been suggested that measurement of the 
ratio of 6-3-cortisol to free cortisol (6-13-F/FF) in the 
urine also provides a means of determining hepatic 
P450IIIA activity in patients. 17,18 Because urinary 
6-13-F/FF measurements are completely noninvasive 
and do not involve radioisotopes, this assay would be 
preferable to the ERMBT in most instances if both as- 
says provided similar information. However, no corre- 
lation between 6-13-F/FF and the erythromycin breath 
test was observed by Hunt et al. 19 in a small number 
of patients with hypertension. To investigate the rela- 
tionship between these breath and urine assays, we ad- 
ministered both tests to 48 patients under a variety of 
experimental conditions. 
METHODS 
Patients studied. A total of 48 patients received 
both the ERMBT and a 24-hour urine collection for 
measurement of 6-13-F/FF. Each patient received their 
ERMBT within 24 hours of completing the urine col- 
lection. A single patient had end-stage liver disease 
and underwent liver transplantation. He is discussed 
separately below (anhepatic man) and in the Results 
section. The remaining 47 patients had no history of 
hepatic or renal dysfunction; chemistries used to as- 
sess the integrity of the liver (transaminases, bilirubin, 
and albumin) and kidney (blood urea nitrogen and cre- 
atinine) were within 20% of the normal range in all 
patients. Twenty-two of these patients were stable in- 
patients who were receiving fixed medication regi- 
mens. The medications and some characteristics of 
these patients have been reported previously (patients 
numbered 1 through 5, 7, 8, 10, 11, 14 through 20, 
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22 through 24, 25, 28, 29, and 3012). The remaining 
25 patients were obtained from a study of 33 outpa- 
tients with psoriasis who were being treated with cy- 
closporine in an experimental protocol. These patients 
were not receiving systemic medications other than 
cyclosporine and are described elsewhere. /4 All 33 
patients enrolled in this study were asked to collect 
their urine at home for 24 hours before their visits to 
the hospital for the ERMBT and other studies. Six pa- 
tients failed to bring in a urine sample, and in two 
cases the urine sample was lost or mislabeled. None 
of the 47 patients was receiving medications known or 
suspected to induce or inhibit the catalytic activity of 
P450IIIA (glucocorticoids, antiseizure medications, 
imidazole, antimycotic drugs, or macrolide antibiot- 
icsio,i 1). 
After the initial urine collections and breath tests, 
several of the hospitalized patients underwent repeat 
urine collections and breath tests after they were vol- 
untarily treated with rifampin (600 mg daily for 4 
days) or triacetyloleandomycin (single 250 mg dose), 
a known inducer and inhibitor, respectively, of 
P450111A.217 We have shown previously that these 
treatment regimens result in significant increases and 
decreases, respectively, in the ERMBT results.12 The 
ERMBT results obtained in these patients have been 
reported previously.12 
The erythromycin breath test. The ERMBT was 
administered and the results were analyzed as previ- 
ously described. 12 The results were expressed as the 
percentage of administered carbon 14 exhaled in the 1 
hour after the intravenous injection of C4C-N-methyd- 
erythromycin. We have shown that there is less than a 
20% intrapatient variability in the ERMBT result 
(Watkins et al. /2 and Watkins P, unpublished data, 
March 1992). In the patients receiving cyclosporine, 
all breath tests were performed before the medication 
was started. 
Measurement of urinary 6-11-FIFF. Urine was col- 
lected for 24 hours in a single container. The total 
voided volume was measured, and aliquots were fro- 
zen and stored at 20° C. Aliquots were batched and 
sent on ice to the laboratory of Dr. Saenger. 6-13-Cor- 
tisol concentration was determined by a radioimmuno- 
assay that has been previously validated.20'21 Paired 
aliquots of urine were also shipped to Hazelton Labo- 
ratories, Vienna, Va., where free cortisol concentra- 
tion was determined by radioimmunoassay.22 
Blood measurements of cyclosporine. Cyclosporine 
was measured in whole blood by an HPLC tech- 
nique.23 
Studies in an anhepatic man. Urine was collected 
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from and the ERMBT was administered to a 31-year- 
old man who underwent liver transplantation for end- 
stage liver disease attributed to chronic non-A, non-B 
hepatitis. During surgery, there is a 2- to 3-hour inter- 
val in which the patient is anhepatic; that is, the dis- 
eased liver is removed from the recipient's body but 
perfusion to the donor liver has not yet been estab- 
lished. During this interval, blood from the inferior 
vena cava (which drains the lower extremities and the 
kidneys) and blood from the portal vein (which drains 
the intestine) is diverted by tubing to an extracorporeal 
pump. The pump feeds the blood back through a cath- 
eter into the left subclavian vein. In this way, blood 
perfusion is maintained to all the body tissues. 
The ERMBT was administered and consecutive 15- 
minute urine samples were obtained during this pa- 
tient's anhepatic state. For the breath test, the pa- 
tient's exhaled breath was sampled by placing a 
T-tube into the exhalation tubing of the patient's res- 
pirator. Urine samples were obtained from an indwell- 
ing urinary catheter. 
Statistical analysis. The strength of the linear rela- 
tionship between the ERMBT and 6-13-F/FF results 
was assessed with Pearson's product-moment correla- 
tion coefficient. Selection of the best set of variables 
for predicting cyclosporine blood levels was per- 
formed with a forward stepwise multiple linear regres- 
sion analysis whereby potential predictor (indepen- 
dent) variables were sequentially included or excluded 
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from the model according to the strength of their re- 
spective partial correlations. The dependent variable 
was expressed in the common logarithms of the mean 
cyclosporine blood levels to provide a better linear fit 
to the model. Rationale for the selection of the inde- 
pendent variables examined has been reported previ- 
ously.14 
All p values are two tailed. The data were analyzed 
with the Michigan Interactive Data Analysis System 
(MIDAS), a statistical software package developed by 
the Statistical Research Laboratory at the University 
of Michigan (Ann Arbor, Mich.). 
RESULTS 
ERMBT results and 6-13-FIFF ratios. Twenty- 
four-hour urine collections were obtained from and the 
ERMBT was administered to 47 patients who had no 
clinical evidence of liver disease. These patients were 
not receiving medications known or suspected to in- 
fluence the activity of P450IIIA (see Methods). In 
Fig. 1, the results of the urine 6f3-F/FF ratios are 
compared with the corresponding ERMBT results ob- 
tained for each patient. There was a positive correla- 
tion between the breath test result and 6-13-F excretion 
in urine that was highly statistically significant (r = 
0.59, p = 0.0001). However, when the individual 
with the highest breath test result (7%) and the indi- 
vidual with the highest urinary 6-I3-F/FF23 were ex- 
cluded from the analysis, the correlation between the 
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Fig. 1. Correlation between the erythromycin breath test (ERMBT) result and urinary 6-13- 
cortisol/free cortisol ratio (6-I3-F/FF) in 47 patients. Patients collected their urine for 24 hours be- 
fore receiving the ERMBT. The ERMBT was performed and urine 6-13-F/FF was assayed as de- 
scribed in the Methods section. Solid circles, men; open circles, women. 
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two tests was less impressive (r = 0.4, p < 0.006). 
No patient with a very low ERMBT result (<1.5%) 
had a high urine 6-13-F/FF ratio (>5.0). However, 
some patients with a high ERMBT result (>3.0%) 
had a low urinary 6-13-F/FF ratio (<5.0: Fig. 1). 
The mean breath test result was higher in women 
than in men (3.14% and 2.29%, respectively, p < 
0.02. unpaired t test). Mean urine 6-13-F/FF ratios 
were also higher in women than men (8.5 and 5.17, 
respectively, p < 0.01, unpaired t test). This gender 
effect largely accounted for the correlation between 
the two assays. However, when the 34 men and 13 
women were analyzed separately, the correlation be- 
tween the results of the two tests remained significant 
(r = 0.37, p = 0.03 and r = 0.64, p = 0.03, respec- 
tively). 
Effect of treatment with rifampin and triacetylole- 
andomycin. Immediately after the urine collection 
and breath testing, four patients received the 
P450IIIA-inducer rifampin and underwent repeat 
urine collection and breath testing. Rifampin treat- 
ment resulted in increases in both urinary 6-13-F/FF 
and in erythromycin N-demethylation in each patient 
(Fig. 2, A). However, in one patient (Fig. 2, A, 
hollow triangles) the rifampin treatment resulted in a 
nearly threefold increase in urinary 6-13-F/FF, whereas 
the patient's breath test result remained almost un- 
changed. 
An additional four patients received a single dose of 
the selective P45011IA inhibitor triacetyloleandomy- 
cin. The breath test was readministered 2 hours after 
the triacetyloleandomycin dose and urine was col- 
lected during the subsequent 24 hours. As can be seen 
in Fig. 2, B, triacetyloleandomycin treatment ap- 
peared to have discordant effects on the results of each 
test. There was a marked decrease in erythromycin 
demethylation in each patient, whereas 6-I3-F excre- 
tion actually increased in two patients. 
Studies in an anhepatic man. We next studied a 
30-year-old man who underwent liver transplantation 
for severe chronic liver disease. Urine was collected 
and the ERMBT was administered before the liver 
transplant procedure and again after surgery when the 
patient was medically stable. The tests were also ad- 
ministered to the patient intraoperatively during the 
anhepatic phase of the liver transplant operation (see 
Methods section). 
As can be seen in Fig. 3, A, the patient's breath test 
results were considerably higher after the transplant 
procedure than before. During the anhepatic phase, 
production of carbon dioxide from erythromycin de- 
creased dramatically (>85% compared with the pre- 
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transplant value and >90% compared with the post- 
transplant value). The ratio of 6-13-F/FF in the urine 
did not follow a similar pattern. The urinary 6-13-F/FF 
ratio was actually higher in the individual before he 
underwent liver transplantation than after he had re- 
ceived the healthy donor liver (Fig. 3, B). During the 
anhepatic phase, the rate of production of free cortisol 
in the urine and the rate of urine production remained 
constant (data not shown). As can be seen in Fig. 3, 
B, the ratio of 6-13-F/FF, which was measured in se- 
quential 15-minute urine collections, decreased ap- 
proximately 50% during the first hour but then ap- 
peared to plateau, remaining roughly constant for the 
final 1 1/2 hours of the anhepatic state. The marked de- 
crease in the urinary 6-13-F/FF observed when the do- 
nor liver was reperfused (Fig. 3, B, arrow) may be re- 
lated to the significant blood loss and simultaneous 
infusion of donor blood that occurred during this pe- 
riod. 
6-fl-Cortisol as a predictor of cyclosporine blood 
levels. The above studies show that the urine 6-(3-F/FF 
ratio and the ERMBT result do not always give sim- 
ilar results. Because one of the potentially important 
uses for noninvasive assays of P450IIIA activity may 
be to guide physicians in correct dosing of drugs that 
are P45011IA substrates, we wanted to determine 
which of the two tests was most useful in this regard. 
We have reported that the ERMBT significantly corre- 
lated with the logarithm of the mean trough blood 
level of cyclosporine in 32 patients who received the 
drug as an experimental treatment for psoriasis. '4 Our 
sample of 47 patients (Fig. I) included 25 patients en- 
rolled in this study. Each patient was randomized to 
receive one of three doses of cyclosporine (3.0, 5.0, 
or 7.5 mg/kg/day) and had monthly trough blood lev- 
els of cyclosporine determined in whole blood by 
HPLC. One patient was documented to have poor 
compliance with his cyclosporine and was excluded 
from the analysis in our previous study. 4 We there- 
fore analyzed the data obtained in the remaining 24 
patients. 
To compare urinary 6-13-F/FF measurements with 
the ERMBT as a predictor of mean trough cyclospor- 
ine blood levels, we performed a multiple regression 
analysis with the logarithm of the mean cyclosporine 
blood level as the dependent variable and cyclosporine 
dose, urinary 6-13-F/FF ratio, ERMBT result, patient 
age, and other patient characteristics or laboratory pa- 
rameters as the independent variables (Table I). In the 
first step of the regression (Table I, step 1), cyclospor- 
ine dose, ERMBT, and patient age were the only vari- 
ables that significantly correlated with the cyclospor- 
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me blood levels (p < 0.05). The cyclosporine dose 
was superior to the other variables as a predictor of 
drug blood level and was incorporated into the model 
in the first regression step. After interpatient differ- 
ences in dose of cyclosporine received were thus 
taken into account, the ERMBT result and patient age 
were the only significant predictors of cyclosporine 
trough blood levels (Table I, step 1). Urinary 6-13- 
F/FF did not appear to have any predictive value in 
the model before or after the ERMBT values were in- 
corporated into the model (Table I, steps 1 and 2, re- 
spectively). 
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Fig. 2. Changes in the results of the ERMBT (left) and the urinary 6-0-F/FF (right) in patients 
treated with 600 mg/day rifampin for 4 days (A) and a single oral dose of 250 mg triacetylolean- 
domycin (B). Patients received both tests before and after the indicated treatment. Lines connect 
the results obtained for each individual. 
12 
10 
8 
4 
2 
DISCUSSION 
The primary goal of our study was to determine 
whether the ERMBT and urine 6-I3-F/FF yielded com- 
parable information. These tests were comparable in 
that 6-13-F/FF ratio measured in the urine correlated 
significantly with the ERMBT test result in the initial 
47 patients studied (Fig. 1). Moreover, the mean of 
the results for both tests was higher in women than in 
men, which is consistent with earlier reports. 12.24 In 
addition, we found that both the urine 6-f3-F/FF and 
the ERMBT result increased in patients after they 
were treated with the P450IIIA inducer rifampin, con- 
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Fig. 3. Changes in the rate of production of carbon dioxide 
(CO,) from erythromycin (A) and in urinary 6-13-F/FF (B) in 
a patient undergoing liver transplantation for severe end- 
stage liver disease. The patient underwent testing before 
(open circles) and after (solid circles) the liver transplanta- 
tion procedure. In addition, the patient received an intrave- 
nous injection of ["C-N-methyl]-erythromycin and had 
sequential 15-minute urine collections for 6-13-F/FF mea- 
surements during the anhepatic phase of the liver trans- 
plant procedure (boxes). The rate of CO, production from 
erythromycin was estimated from the specific activity of 
CO, in the breath sample collected at each time point and an 
estimation of the endogenous rate of production of CO2.12 
The arrow (B) indicates the end of the anhepatic phase 
(when the donor liver was connected to the recipient's blood 
circulation). 
firming earlier observations.12'17 Finally, the results of 
both tests decreased significantly during the anhepatic 
state, suggesting that hepatic P45011IA enzymes were 
largely being measured by both tests. 
Nonetheless, striking differences between the re- 
sults of the two tests were observed in some instances. 
100 
Some patients with relatively high breath test results 
had relatively low urinary 6-13-F/FF ratios (Fig. I). In 
one patient, rifampin treatment resulted in a large rel- 
ative increase in urine 6-13-F/FF but a minimal change 
in the breath test result (Fig. 2, A). In addition, 
whereas a single dose of triacetyloleandomycin dra- 
matically inhibited erythromycin demethylation in 
each of the four patients studied, this treatment re- 
sulted in an increase in the urinary 6-B-F/FF ratio in 
two of them (Fig. 2, B). It should be remembered that 
the urinary measurements reflect the mean production 
of 6-13-F over 24 hours, whereas erythromycin de- 
methylation was determined over 1 hour (2 hours after 
administration of triacetyloleandomycin). This may be 
important because triacetyloleandomycin appears to 
induce P450111A and to inhibit the enzyme.2 It is 
therefore possible that transient inhibition of P45011IA 
activity by triacetyloleandomycin followed by induc- 
tion of P45011IA catalytic activity could explain the 
discrepancy between the ERMBT and 6-13-F/FF re- 
sults. 
There was also a marked difference between the re- 
sults of each test performed before and after our pa- 
tient underwent liver transplantation. Replacement of 
our recipient's diseased liver with a healthy donor 
liver resulted in a marked increase in the ability of the 
patient to demethylate erythromycin as we have ob- 
served in nine other patients undergoing liver trans- 
plantation. 15 In contrast, liver transplantation resulted 
in a decrease in urinary 6-13-F/FF (Fig. 3, B). 
It is not clear from our data why there is a disparity 
between the urine and breath test results. It is unlikely 
that this reflects a problem with the collection of urine 
because 6-0-F/FF does not appear to show much diur- 
nal variation; therefore a complete 24-hour collection 
should be unnecessary (Bienvenu et al.,18 Saenger,2° 
and Saenger P, unpublished observations, March 
1992). Some clues to the basis for the discrepancy 
may be provided by our studies during the anhepatic 
state. There was a dramatic reduction in the rate 
of CO2 production from erythromycin during the 
anhepatic state (Fig. 3, A). This is consistent with 
our assumption that the major site of metabolism of 
the intravenously administered dose of erythromycin 
would be the liver. However, P450IIIA enzymes are 
present in some extrahepatic tissues where they may 
catalyze significant metabolism. Human jejunal mu- 
cosa and kidney contain protein and messenger ribo- 
nucleic acid closely related to the P45011IA family 
of enzymes.2526 Orally administered substrates for 
P450IIIA appear to undergo significant first-pass me- 
tabolism by P450IIIA in the gllt,27'28 but it is not 
(TIN pHARmAcot, THER 
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Table I. Summary of the stepwise selection procedure used in creating a multiple regression model capable of 
predicting the logarithm of the observed mean cyclosporine blood level 
known whether intravenously administered substrates 
undergo significant intestinal metabolism. Likewise, 
the contribution that renal P450IIIA enzymes make to 
metabolism of P450IIIA substrates is not known. If 
there is significant extrahepatic metabolism of the in- 
travenously administered erythromycin, it could have 
been missed in our anhepatic phase study if general 
anesthesia or the removal of the liver dramatically al- 
tered one carbon pool kinetics. The former is unlikely 
because a dramatic decrease in the ERMBT result was 
not seen when we administered the ERMBT to a pa- 
tient with an intact liver while he was receiving gen- 
eral anesthesia (unpublished observations, March 
1992). The latter possibility cannot be excluded be- 
cause the contribution of extrahepatic enzymes to one 
carbon pool kinetics is not known. However, our pre- 
vious direct demonstration of the correlation between 
the ERMBT result and liver levels of P450IIIA'5 sup- 
ports the idea that the ERMBT mainly reflects hepatic 
P450IIIA activity. 
The rate of 6-13-F elimination also decreased 
sharply during the first hour of the anhepatic state. 
The observed rate of decline is in good agreement 
with the serum half-life of 6-13-F of 48 minutes29 and 
ERMBT, Erythromycin breath test; HDL, high-density lipoprotein; 6-13-F/FF, ratio of 6-13-cortisol to free cortisol in urine; LDL, low-density lipoprotein. 
*Variables listed at each regression step are in rank order of predictive capacity. The variables in italics were selected for incorporation into the model at that step. 
tPartial correlation coefficient. 
(Coefficient of multiple determinations reflecting the predictive capacity of the model after incorporation of the variable selected at that step (italicized). At step 2. 
the coefficient (0.71) reflects the predictive capacity of the model incorporating both the dose and ERMBT terms. 
supports a hepatic component to the metabolism mea- 
sured by the urine test. However, our data are incon- 
sistent with the assumption that the urinary 6-13-F/FF 
ratio mainly reflects hepatic metabolism. After the 
first hour of the anhepatic state, the rate of 6-13-F se- 
cretion remained at roughly 50% of the original value 
until the donor liver was perfused (Fig. 3, B). More- 
over, the 6-13-F/FF ratio was quite high when the pa- 
tient had end-stage liver disease (before surgery) and 
actually decreased after he received a new liver. These 
observations strongly suggest that a component of the 
6-13-F measured in urine is derived from extrahepatic 
sources. One likely source for extrahepatic production 
of 643-F is the kidney. Greater amounts of 6-13-F are 
found in urine than can be accounted for by simple 
plasma filtration3° and human kidney tissue slices are 
capable of forming the 6113-hydroxy metabolite from 
cortiso1.3' The adrenal gland also appears to be capa- 
ble of producing 6-43-F.3° 
Our suggestion that urinary 6-13-F does not always 
provide an accurate assessment of hepatic P45011IA 
activity is consistent with data presented by Ged et 
al.17 These investigators measured urinary 6-13-F/FF 
and performed liver biopsies on patients before and af- 
Step Variable* Rt p Value R21 
Dose 0.66 0.005 0.43 
ERMBT 0.70 0.0002 
Age 0.50 0.016 
HDL cholesterol 0.39 0.065 
Weight 0.35 0.102 
Gender 0.32 0.138 
Triglycerides 0.26 0.228 
6-13-F/FF 0.24 0.280 
LDL cholesterol 0.17 0.446 
Total cholesterol 0.17 0.446 
Body surface area 0.12 0.575 
2 ERMBT 0.70 0.0002 0.71 
Age 0.46 0.032 
Weight 0.27 0.221 
Triglycerides 0.25 0.253 
Body surface area 0.20 0.363 
Gender 0.13 0.572 
LDL cholesterol 0.12 0.590 
HDL cholesterol 0.05 0.833 
6-I3-F/FF 0.02 0.913 
Total cholesterol 0.02 0.932 
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ter they were treated with rifampin. They found that 
liver P450IIIA levels and urine 6-3-F/FF each in- 
creased when patients were treated for several days 
with this P450IIIA inducer. When results obtained in 
these patients both before and after treatment were 
considered in aggregate, there was a significant corre- 
lation between 6-13-F/FF and liver P450IIIA levels. 
However, if the results obtained in patients before or 
after treatment with rifampin are analyzed separately, 
there was no correlation at all between urine 6-13-F/FF 
and liver P450IIIA levels." 
Regardless of the relative contribution that hepatic 
and extrahepatic enzymes make to the results of each 
test, a clinically relevant question is which test pro- 
vides the most useful information regarding individu- 
alized dosing of administered P450IIIA substrates. In 
this regard, the ERMBT was clearly superior as a pre- 
dictor of mean trough cyclosporine levels in our study 
(Table I). Indeed, the urinary 6-13-F/FF measurements 
did not at all correlate with the cyclosporine blood 
levels observed in the patients. 
In summary, we found a significant correlation be- 
tween the ERMBT result and urinary 6-13-F/FF ratio 
when all patients studied were considered. However, 
there were marked discrepancies between the results 
of the two assays in some patients, clearly indicating 
that the tests do not always give similar information 
about the status of P450IIIA catalytic activity in a pa- 
tient. Of the two tests, the ERMBT would appear to 
provide the most relevant information for individual- 
ization of the dosing of substrates of P450IIIA. Our 
findings point out the importance of considering extra- 
hepatic enzyme activity when designing noninvasive 
means of measuring liver oxidative metabolism. 
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